Stacking two GLP agents isn't inherently riskier than dose escalation - the side-effect difference depends on which receptors you're adding and what that introduction does to your GI baseline.
The compounding pharmacy supply question is worth thinking about from an inventory angle - the windows where access gets tighter have been real. Building a buffer while you can is a rational response to that uncertainty.